Stephen V Liu and Fabrice Barlesi
May 11, 2025, 09:37
Stephen V Liu: Overview of ROS1 in NSCLC by Dr. Fabrice Barlesi at Rome Lung 2025
Stephen V Liu, Director of Thoracic Oncology, Head of Developmental Therapeutics and Associate Professor at the Georgetown Lombardi Comprehensive Cancer Center, shared a post on X:
“Overview of ROS1 in NSCLC by Dr. Fabrice Barlesi at Rome Lung 2025?
Three approved drugs – crizotinib, entrectinib, most recently, repotrectinib – all very active agents. At progression, lorlatinib may be an option at progression but chemotherapy is active with emerging agents like NVL -510.”
More posts featuring Stephen V Liu on OncoDaily.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 4, 2025, 16:17
Sep 4, 2025, 16:08
Sep 4, 2025, 15:59
Sep 4, 2025, 15:51
Sep 4, 2025, 15:49
Sep 4, 2025, 15:48
Sep 4, 2025, 15:36
Sep 4, 2025, 15:34